Ajanta Pharma shares fall nearly 1% amid high volume; stock among top losers on Nifty Midcap 150

Shares of Ajanta Pharma experienced a decline of 0.97% to Rs 2,453.60 in Monday's session amid volume surge. The stock is among the top losers on Nifty Midcap 150.

The company's consolidated financial performance reveals steady growth. Revenue for the quarter-ending June 2025 stood at Rs 1,302.65 Crore, compared to Rs 1,144.92 Crore in June 2024, marking an increase. Net profit for the same period was Rs 255.34 Crore, up from Rs 245.77 Crore in the previous year. The Earnings Per Share (EPS) also increased to Rs 20.44 in June 2025 from Rs 19.54 in June 2024.

The consolidated annual financial data shows consistent growth over the years. Revenue increased from Rs 2,889.69 Crore in 2021 to Rs 4,648.10 Crore in 2025. Net profit also rose from Rs 653.87 Crore in 2021 to Rs 920.39 Crore in 2025. Similarly, EPS increased from Rs 75.09 in 2021 to Rs 73.56 in 2025. Book Value Per Share (BVPS) grew from Rs 344.52 in 2021 to Rs 302.38 in 2025. The Return on Equity (ROE) also showed a positive trend, increasing from 21.82% in 2021 to 24.28% in 2025. The company's debt-to-equity ratio remained at 0.00 throughout the period.

The income statement for the year ending March 2025 shows sales of Rs 4,648 Crore, other income of Rs 94 Crore, and total income of Rs 4,742 Crore. Total expenditure amounted to Rs 3,532 Crore, resulting in an EBIT of Rs 1,209 Crore. Interest expenses were Rs 20 Crore, and tax expenses were Rs 268 Crore, leading to a net profit of Rs 920 Crore.
The balance sheet for March 2025 shows a share capital of Rs 25 Crore and reserves & surplus of Rs 3,765 Crore. Total liabilities amounted to Rs 5,014 Crore, while total assets were also Rs 5,014 Crore. The cash flow statement indicates a net cash flow of Rs 47 Crore, with Rs 1,157 Crore from operating activities, -Rs 376 Crore from investing activities, and -Rs 733 Crore from financing activities.

Key financial ratios for Ajanta Pharma as of March 2025 include a basic EPS of Rs 73.56, diluted EPS of Rs 73.53 and a book value per share of Rs 302.38. The company's dividend per share was Rs 28.00. Margin ratios include a gross profit margin of 29.13%, operating margin of 26.02%, and net profit margin of 19.80%. Return ratios show a return on net worth/equity of 24.28%, ROCE of 30.10%, and return on assets of 18.35%. Liquidity ratios include a current ratio of 2.85 and a quick ratio of 1.95. Leverage ratios indicate a debt to equity ratio of 0.00 and an interest coverage ratio of 65.32. Valuation ratios show a P/E ratio of 35.66, P/B ratio of 8.66, EV/EBITDA of 24.11 and P/S ratio of 7.06.

Ajanta Pharma announced an interim dividend of Rs 28 per share on October 25, 2024, with an effective date of November 6, 2024. Earlier, the company had announced a bonus issue on May 10, 2022, with a ratio of 1:2 and an ex-bonus date of June 22, 2022.

As of September 1, 2025, Moneycontrol analysis indicates very bearish sentiment on the stock.

With the stock's last traded price at Rs 2,453.60, Ajanta Pharma experienced a decline amid high volume in today's session, with the stock included as one of the stocks in the Nifty Midcap 150 index.